EuroPCR

New Horizons in Tricuspid Therapy

Wednesday May 19th 2021
New Horizons in Tricuspid Therapy

Our TNT session at EuroPCR addressed the problems of tricuspid regurgitation and explained the unique TricValve Transcatheter Bicaval system solution.

Hear from the experts

M Haude
M A Rosli
K Kiss
I Amat-Santos
Y S Azmi
M Azmee

Concluding remark

Prof Haude concluded the session with key a take-home message; “TricValve implantation is safe, and the minimally invasive procedure seems feasible to treat severe TR with low complication rates.”

Learning Objectives

  • To learn about the TricValve system’s approach to tricuspid regurgitation and right heart disease
  • To understand how this new generation of tricuspid valve system may reduce the procedural time and contribute to patients’ prognostic
  • To obtain first insights on real live case scenario

Case summary

A 67-year-old female patient was admitted with signs of right heart failure with NYHA class III. The patient had a history of chronic hypertension, dyslipidaemia and atrial fibrillation. She was diagnosed with Severe Functional Tricuspid Regurgitation with secondary to Chronic Fibrillation. Left ventricle EF was 38% with right atrium and ventricular dilatation. Echocardiogram showed a mild functional Mitral valve, severe functional Tricuspid valve, poor coaptation of Tricuspid valve leaflets, and reversal of hepatic vein systolic flow. She refused any surgical valve replacement due to high surgical risk. Therefore, she agreed to go for a transcatheter TricValve® implantation.